The Net Margin of Vir Biotechnology, Inc. (VIR) is
-638.87%.
Net Margin measures the percentage of net income derived from total revenue after all expenses. It signals how much actual profit a company retains from its sales.
| Date |
Value |
| 2025-12-31 |
-638.87%
|
| 2024-12-31 |
-703.40%
|
| 2023-12-31 |
-713.69%
|
| 2022-12-31 |
31.92%
|
| 2021-12-31 |
48.26%
|
| 2020-12-31 |
-390.97%
|
| 2019-12-31 |
-2156.79%
|
| 2018-12-31 |
-1083.18%
|
| 2017-12-31 |
-2588.89%
|
| Ticker |
Name |
Value |
|
ABBV
|
AbbVie Inc.
|
6.91%
|
|
MDGL
|
Madrigal Pharmaceuticals, Inc.
|
-30.08%
|
|
PGEN
|
Precigen, Inc.
|
-2588.21%
|
|
PTCT
|
PTC Therapeutics, Inc.
|
39.44%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
-3733.25%
|
|
MORF
|
Morphic Holding Inc
|
-29192.90%
|
|
MYGN
|
Myriad Genetics, Inc.
|
-44.38%
|
|
VCEL
|
Vericel Corporation
|
5.98%
|
|
HRTX
|
Heron Therapeutics Inc
|
-13.04%
|
|
TWST
|
Twist Bioscience Corporation
|
-28.34%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
32.94%
|
|
950200.KQ
|
Psomagen Inc
|
-5.04%
|
|
AMRN
|
Amarin Corporation PLC
|
-18.16%
|
|
GILD
|
Gilead Sciences, Inc.
|
28.90%
|
|
MGNX
|
MacroGenics Inc
|
-49.91%
|
|
MRNA
|
Moderna, Inc.
|
-145.16%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
31.41%
|
|
ACAD
|
Acadia Pharmaceuticals Inc.
|
36.49%
|
|
ARWR
|
Arrowhead Pharmaceuticals, Inc.
|
-160.64%
|
|
EXEL
|
Exelixis Inc
|
33.73%
|
|
ZNTL
|
Zentalis Pharmaceuticals, Inc.
|
-245.96%
|
|
950220.KQ
|
Neoimmunetech Inc
|
-33533.01%
|
|
AMGN
|
Amgen Inc
|
20.98%
|
|
BBIO
|
BridgeBio Pharma, Inc.
|
-144.39%
|
|
INSM
|
Insmed Incorporated
|
-210.54%
|
|
SRRK
|
Scholar Rock Holding Corporation
|
-405.21%
|
|
XNCR
|
Xencor, Inc.
|
-73.20%
|
|
AGIO
|
Agios Pharmaceuticals, Inc.
|
-764.01%
|
|
BCRX
|
BioCryst Pharmaceuticals, Inc.
|
30.16%
|
|
EDIT
|
Editas Medicine, Inc.
|
-395.01%
|
|
NBIX
|
Neurocrine Biosciences, Inc.
|
16.73%
|
|
SRNE
|
Sorrento Therapeutics Inc
|
-912.10%
|
|
CBPO
|
China Biologic Products Holdings Inc
|
29.04%
|
|
NTRA
|
Natera, Inc.
|
-9.03%
|
|
ORGO
|
Organogenesis Holdings Inc.
|
6.56%
|
|
TVTX
|
Travere Therapeutics, Inc.
|
-5.21%
|